CD33 and neoplasm: The ex vivo biodistribution results confirmed the in vivo results, with a significant higher tumor targeting for anti-CD33 Nb_12, Nb_87, Nb_21, and Nb_7 compared to Nb_16 and to the non-targeting control 99mTc-ctrl_Nb.